Dr. Meyer has a focus on the study of human immune tolerance in the hematopoietic stem cell setting and islet cell transplantation. He studies murine pre-clinical models with a focus on T cell immunotherapy, T regulatory cell and invariant NKT cell biology and non-myeloblative hematopoietic stem cell transplantation for tolerance induction. In established collaborations with Dr. Seung Kim, Dr. Meyer has developed genetic engineering to reprogram Tregulatory cells to target them to mouse islet allografts and human islet xenografts. This approach has resulted in some startling discoveries: (1) genetically engineered Tregulatory cells producing Chimeric Antigen Receptor (CAR) are much better at preventing islet graft rejection than normal Tregulatory cells and (2) genetically engineered Tregulatory cells can alter the immune system to create new immune memory and tolerance. Together with several members of the Stanford Diabetes Research Center (SDRC) and SDRC Islet Research Core, Dr. Meyer is leading efforts to establish a human islet auto-transplant program at Stanford.
Dr. Meyer has worked collaboratively with Drs. Kim, Shizuru and Tang and will co-lead the efforts of Project 2. Dr. Meyer is a practicing physician-scientist who is overseeing two clinical trials, one of which is a Stanford IND, investigator‐lead phase I/II study using purified donor‐derived T regulatory cells to prevent graft‐versus‐host disease following hematopoietic cell transplantation. As the co‐director of Core C, Dr. Meyer will share responsibility for the administration and coordination of effort, including overall responsibility for analysis, interpretation and dissemination, and sharing of data and resources.